register

News & Trends - MedTech & Diagnostics

Medtronic partners with local researchers in stroke trial

Health Industry Hub | March 1, 2024 |

MedTech & Diagnostics News: Endovascular thrombectomy has been shown to be more effective in reducing disability than medical therapy alone in selected patients with ischemic stroke due to a large cerebral vessel occlusion. The Hunter Medical Research Institute (HMRI) has joined forces with Titan Neuroscience and medtech company Medtronic to spearhead the FRONTIER AP clinical trial, marking a significant leap forward in stroke treatment.

Serving as the Academic Research Organisation (ARO) and Sponsor for the Melbourne-based trial, HMRI is set to propel the evaluation of a novel treatment called Endovascular Clot Retrieval or thrombectomy for acute ischaemic stroke. This innovative approach, which has already demonstrated its efficacy in removing clots from large vessels in stroke patients, is now advancing to its Phase 2 trial to assess applicability in medium vessels, potentially unlocking new dimensions in stroke care.

Todd Williams, HMRI’s Chief Partnership and Development Officer, expressed his enthusiasm for the partnership, emphasising HMRI’s commitment to delivering transformative health solutions.

“Our whole reason for existing is to transform the health and wellbeing of our communities, and this is just another way we are partnering with industry to advance health outcomes,” said Mr Williams. He highlighted the collaboration with Hunter New England Local Health District, University of Newcastle, and the Primary Health Network, reinforcing HMRI’s capability to lead world-class clinical trials.

The collaboration leverages a confidential technology from Medtronic, promising to expand horizons in stroke treatment and recovery. Titan Neuroscience Research, a leading healthcare research company based in Melbourne, is entrusted with conducting the clinical trial.

Professor Mark Parsons, a world-renowned stroke neurologist and Co-Founder of Titan, highlighted the immense potential of Australian industry and medical research partnerships in driving technology innovation in clinical trials.

“This is just the first step in what we hope will be a fruitful, long-term partnership with HMRI,” remarked Professor Parsons.

The Phase 2 trial is set to recruit 240 adult patients presenting with acute ischaemic stroke within nine hours of onset. The trial commenced in January 2024 and is expected to run for approximately five years, encompassing stroke centres nationally and internationally across Australia and the Asia Pacific.

In reimagining healthcare across the entire patient journey, Health Industry HubTM is the only one-stop-hub bringing the diversity of Pharma, MedTech, Diagnostics & Biotech sectors together to inspire meaningful change.

The content on Health Industry Hub is copyright protected and should only be accessed under individual user licenses. To subscribe, please click here and visit T&Cs here.


News & Trends - Biotechnology

AusBiotech appoints new CEO: Former Sanofi corporate affairs and sustainability leader takes the helm

AusBiotech appoints new CEO: Former Sanofi corporate affairs and sustainability leader takes the helm

Health Industry Hub | April 23, 2024 |

Biotech News: AusBiotech, the nation’s leading industry body for the biotech sector, has named former leader at Sanofi, Rebekah Cassidy, […]

More


News & Trends - MedTech & Diagnostics

Federal government invests in Siemens Healthineers scanner to 'reduce wait times' for cancer diagnosis

Federal government invests in Siemens Healthineers scanner to ‘reduce wait times’ for cancer diagnosis

Health Industry Hub | April 23, 2024 |

MedTech & Diagnostics News: The Albanese Government is investing $12 million through the 2024–25 Budget, to purchase and install a […]

More


News & Trends - MedTech & Diagnostics

Cardiac device benefits face more cuts, while technical services remain secure in the short term

Cardiac device benefits face more cuts, while technical services remain secure in the short term

Health Industry Hub | April 23, 2024 |

MedTech & Diagnostics News: Starting from July 2024, Cardiac Implantable Electronic Devices (CIED) listed on the Prescribed List (PL) will […]

More


News & Trends - Biotechnology

CSL's world-first gene therapy heads for MSAC assessment

CSL’s world-first gene therapy heads for MSAC evaluation

Health Industry Hub | April 23, 2024 |

Biotech News: CSL’s world-first gene therapy for haemophilia B is scheduled for consideration at the upcoming Medical Services Advisory Committee (MSAC) […]

More


This content is copyright protected. Please subscribe to gain access.